# Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Source: https://onco.cc/trials/nct07098988/  
OnCo record `nct07098988` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Visugromab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by CatalYm GmbH, now recruiting.

## Summary

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC is a phase 2 interventional study registered as NCT07098988 by CatalYm GmbH, with 107 participants planned, started 2025-08-01 and due to reach its primary completion in 2029-03-31. Interventions recorded: Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2, Carboplatin AUC 5. Conditions listed: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07098988
- Phase: 2
- Setting: A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)
- Sponsor: CatalYm GmbH
- Enrolled: 107

## Sources

- ClinicalTrials.gov NCT07098988: https://clinicaltrials.gov/study/NCT07098988

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Visugromab](https://onco.cc/drugs/visugromab/)
- companies: [CatalYm](https://onco.cc/companies/catalym/)

---
JSON: https://onco.cc/api/v1/entities/nct07098988.json